This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abiomed Announces Several Reimbursement Milestones

  • Four Commercial Insurers Institute Broad Impella Coverage
  • Impella Economic Study Published in The Journal of Managed Care Medicine (JMCM)

DANVERS, Mass., March 4, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today provided a reimbursement update. Abiomed announced several recent Impella coverage decisions from national payers including Humana, UnitedHealthcare, Independence Blue Cross and Capital BlueCross. The recently updated coverage decisions include new Impella policies in the payers' commercial and/or Medicare Advantage plans.

Additionally, an economic study on the use of percutaneous ventricular assist devices (pVAD) was published in the February edition of The Journal of Managed Care Medicine ( JMCM), "A Budget Impact Model to Estimate the Cost Dynamics of Treating High-Risk Heart Failure Patients with Advanced Percutaneous Cardiac Assist Devices: The Payer Perspective."

The study developed a Budget Impact Model (BIM) to estimate the annual direct medical costs of treatment and the combined incremental budget impact of introducing a pVAD treatment option. A BIM is a standard approach used by most commercial payers today to assess impact on their spend per member. The study concluded that the per-member per-month (PMPM) impact of the use of pVADS in very challenging patient populations was minimal throughout the technology adoption curve and that patients did not require expensive readmissions for hospital care.

"In this era of healthcare reform, these models help identify the most effective and efficient ways to manage patients, particularly patients with the potential to generate significant costs if not managed properly," said David Gregory, MPA, FACHE, author of the study and Executive Vice President and Partner, Presscott Associates - A Division of ParenteBeard, LLC.

"New clinical guidelines, coupled with clinical and economic studies like this, are all paving the way for Impella to become the new standard of care," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs